The media reports that colchicine, a very old drug, has now been discovered to reduce the risk of recurrent heart disease and has a new FDA indication. Of course, the “discovery” has taken 10 years, ...

The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) represents a completely new ...

Gout is the most common form of inflammatory arthritis, with a worldwide prevalence of approximately 4%. The accumulation of monosodium urate crystals in gout leads to the clinical manifestations of ...

Depending on one’s perspective, the anti-inflammatory colchicine is either an unsung and underprescribed drug for patients with cardiovascular disease, or it’s an agent with limited clinical benefit ...

WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...

Any cardiovascular protection from colchicine in heart attack survivors seemed to be debunked with a better-powered randomized trial, researchers found. Between acute MI patients randomized to ...

Taxpayer dollars spent on colchicine have spiked thanks to a regulatory quirk that enabled a company to exclusively market the centuries-old drug and allowed other manufacturers to follow suit. US ...

Please provide your email address to receive an email when new articles are posted on . Colchicine fails to significantly reduce mechanical ventilation or 28-day mortality in hospitalized patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. If colchicine and its prospects as a COVID-19 treatment ...

Against the sheer scale of morbidity and death due to the ongoing coronavirus disease 2019 (COVID-19) pandemic, the urgency of identifying drugs and other measures that reduce these adverse outcomes ...